R logo Ryder System +
Ryder System
+

Ryder System (R) Business News

Track Ryder System in real time with a live news feed covering Ryder System stock news, official press releases, company announcements, and an archive of historical Ryder System news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Ryder CEO John Diez to Address Wells Fargo 16th Industrials & Materials Conference

Business Wire

6:55 AM | Wednesday | Jun 3, 2026

news photo
Loading...

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials & Materials Conference. Who:  Ryder System, Inc. CEO John Diez What: Wells Fargo 16th Industrials & Materials Conference When:  Wednesday, June 10, 2026 Time: 11:00 a.m.
Central Time Webcast: To access the live webcast, visit Ryder - Wells Fargo 16th Industrials & Materials Conference. About Ryder System, Inc. Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading pro.

Read full article redirect
6:55 AM | Wednesday | Jun 3, 2026

Ryder CEO John Diez to Address Wells Fargo 16th Industrials & Materials Conference

Business Wire

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials & Materials Conference. Who:  Ryder System, Inc. CEO John Diez What: Wells Fargo 16th Industrials & Materials Conference When:  Wednesday, June 10, 2026 Time: 11:00 a.m.
Central Time Webcast: To access the live webcast, visit Ryder - Wells Fargo 16th Industrials & Materials Conference. About Ryder System, Inc. Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading pro.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Jun 1, 2026

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

Accesswire

FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.

Read full article arrow
News Thumbnail
7:30 PM | Friday | May 29, 2026

Core Critical Approved for Listing on OTCQB(R) Venture Market

Accesswire

VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. ("CCMC" or the "Company") (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration company, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares now trade on the OTCQB under the ticker symbol "CCMCF". In addition, the Company is pleased to confirm that its common shares have achieved Depository Trust Company ("DTC") eligibility, greatly facilitating the electronic clearing and settlement of its shares in the United States.

Read full article arrow
News Thumbnail
5:45 PM | Friday | May 29, 2026

Delivra Health and Its Brands Dream Water(R) and LivRelief(TM) Report Results for Third Quarter of Fiscal 2026

Newsfile Corp

Third quarter sales reflect the impact of the continued changes in the global geopolitical landscape that has temporarily impacted outbound shipments from the USA to the Middle East distribution partners Third quarter sales and year-to-date sales growth of Dream Water® Canada E-commerce of 16% and 13% respectively offset by a decline in Dream Water® Canada Retail of 15% and 6% respectively compared to same periods last year Third quarter sales and year-to-date sales growth of LivRelief™ E-commerce of 60% and 32% respectively offset by a decline in LivRelief™ Retail of 30% and 27% respectively compared to same periods last year Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health... Read more

Read full article arrow
News Thumbnail
5:03 PM | Friday | May 29, 2026

Theralase(R) Releases Q1 2026 Financial Statements

Newsfile Corp

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 ("Financial Statements"). Theralase® will be hosting a conference call on June 9 th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026.

Read full article arrow
News Thumbnail
2:50 AM | Thursday | May 28, 2026

New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer

Accesswire

UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer. The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica's FDA 510(k)-cleared DiviTum TKa assay.

Read full article arrow
News Thumbnail
8:50 AM | Wednesday | May 27, 2026

HigherVisibility Introduces Targeted Growth System(R) for Brands Competing in AI Search

Newsfile Corp

The framework centers on site speed, server response, and technical reliability as AI retrieval becomes a filter for citation and discovery. Memphis, Tennessee--(Newsfile Corp. - May 27, 2026) - Leading digital marketing agency HigherVisibility, introduced an updated version of its Targeted Growth System (TGS), a proprietary methodology used across the agency's SEO, PPC, link building, eCommerce SEO, website design, and franchise SEO services.

Read full article arrow
News Thumbnail
6:55 AM | Wednesday | May 27, 2026

Ryder Earns VETS Indexes 3 Star Employer Award for 2026

Business Wire

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been recognized as a 3 Star Employer in the 2026 VETS Indexes Employer Awards, underscoring the company's long‑standing commitment to recruiting, hiring, retaining, developing, and supporting veterans and the military‑connected community. This represents Ryder's second time receiving this honor, following its 2024 designation as a VETS Indexes Recognized Employer. “Ryder is proud to employ so many members of the veteran community and to r.

Read full article arrow
News Thumbnail
4:32 AM | Monday | May 25, 2026

KottonSpa(TM) Debuts World's First Collection of SUPIMA(R) Muslin Baby Essentials.

Newsfile Corp

New York, New York--(Newsfile Corp. - May 25, 2026) - KottonSpa™, a Texas-founded newborn brand that launched in March, introduced a collection of newborn essentials crafted entirely from 100% American-grown SUPIMA® cotton - widely regarded as the world's finest cottons and representing less than 1% of global cotton production. The collection includes SUPIMA® baby accessories, skin-first apparel, and occasion-ready pieces designed for newborns and toddlers ages 0–4 years.

Read full article arrow
News Thumbnail
5:30 PM | Thursday | May 21, 2026

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

Accesswire

BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination... Read more

Read full article arrow
News Thumbnail